Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog.”In the company’s words, NCT06051721 on ClinicalTrials.gov
- Tested for
- Generalized Anxiety Disorder
- Main trialPhase 2
- “The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.”In the company’s words, NCT06051721 on ClinicalTrials.gov
Other drugs for Generalized Anxiety Disorder
- ITI-1284Intra-Cellular Therapies, Inc. · Phase 3
- SEP-363856Otsuka · Phase 3
- BuagafuranBeijing Union Pharmaceutical Factory Ltd · Phase 3
- DT120Definium Therapeutics US, Inc. · Phase 3
- Shugan JieyuSichuan Jishengtang Pharmaceutical Co., Ltd. · Phase 3
- ABBV-932AbbVie · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 14 Oct 2025 | A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026